BMS Industry Symposium

Industry Symposium

Harnessing the Immune System:
New Emerging Data in Multiple Myeloma

Friday 24 May 2024 | 09:30–11:00 CEST
Paris, France

FACULTY

Katja Weisel
Chair

Bio

Katja Christina Weisel

Katja Weisel, MD, is associate professor and Deputy Head the Department of Oncology, Hematology and Bone Marrow Transplantation with Dept. of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg Germany as well as Co-Director of the University Cancer Center Hamburg (UCCH). Prof Weisel received her medical degree from the Medical School of the University of Ulm, Germany, and did her clinical residency in internal medicine at the University of Tübingen, Germany. She did a postdoctoral research fellowship in the laboratory of Developmental Hematopoiesis at the Memorial Sloan-Kettering Cancer Center in New York, NY, USA. She completed her medical fellowship in internal medicine and hematology, oncology at the University of Tübingen. Since 2006, Prof Weisel has been leading the Tübingen myeloma program before she moved to Hamburg in 2019, where she is now deputy head of the hematology and oncology department and the Comprehensive Cancer Center and is leading the myeloma and lymphoma program. Her myeloma research interests focus on treatment optimisation for high-risk myeloma, renally-impaired myeloma patients and further difficult-to-treat patient groups. She is a member of the German Speaking Myeloma Multicenter Group (GMMG) steering committee. Prof Weisel is co-investigator in all GMMG trials and is the lead investigator of several investigator-initiated trials, including the GMMG-CONCEPT trial. Furthermore, she was the principle investigator in several national and international phase I-III trials. Prof Weisel has contributed to more than 250 publications on multiple myeloma treatment and biology.

Salomon Manier
Speaker

Bio

Salomon Manier

Salomon Manier, MD, PhD, is a professor of hematology at Lille University Hospital, in Lille, France. He studied medicine at the University of Paris 5 and spent 4 years as a research fellow at Dana-Farber Cancer Institute in Boston, MA, USA, and was appointed instructor in medicine at Harvard Medical School. After completing his PhD at the University of Lille, Professor Manier became an instructor in hematological malignancies at Lille University Hospital in 2017, an associate professor in 2019, and a professor of hematology in 2022. He is principal investigator of a myeloma research team at the Institut Pasteur de Lille.

Professor Manier’s research interests include hematologic malignancy biomarkers, particularly differential expression of miRNAs in multiple myeloma (MM), permitting stage identification and determining treatment effectiveness. He has worked on defining gene dependency in MYC-overexpressing tumors, and targeting MYC in MM. His current research focuses on immune evolution and MM microenvironment and incorporates BCMA immunotherapies and CAR T cell therapies.

Professor Manier serves on the American Society of Hematology (ASH) Plasma Cell Neoplasia Scientific Committee, on the American Association for Cancer Research (AACR) Myeloma 2020 Scientific Committee, and on the Intergroupe Francophone du Myelome (IFM) Board. He has authored book chapters, articles, and reviews in high-impact, peer-reviewed medical journals and has presented at numerous international congresses.

Charlotte Pawlyn
Speaker

Bio

Charlotte Pawlyn

Charlotte Pawlyn is a CRUK Clinician Scientist at The Institute of Cancer Research and a Haematology Consultant at The Royal Marsden Hospital NHS Foundation Trust.

Dr. Pawlyn received her degrees in Pharmacology and Medicine from St John’s College, Cambridge University, UK. She completed her initial medical training in the East Anglian and North London deaneries and Haematology specialty training at the Royal Marsden Hospital and The Institute of Cancer Research, London. In 2016 Charlotte completed a Wellcome Trust funded PhD Fellowship, undertaking laboratory research to identify novel epigenetic targets for myeloma therapy.

Dr. Pawlyn leads the Myeloma Biology and Therapeutics Team at The Institute of Cancer Research which focusses on identifying therapeutic targets to improve outcomes for patients with immunomodulatory drug resistant and high-risk myeloma. In addition to her laboratory studies Charlotte is actively involved in the Trial Management Groups of several clinical trials as part of the UK Myeloma Research Alliance including the large national frontline studies, Myeloma XI and Myeloma XIV.

Paul G. Richardson
Speaker

Bio

Paul G. Richardson

Paul G. Richardson, MD, is the R.J. Corman Professor of Medicine at Harvard Medical School, Boston, MA, USA, and clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (DFCI). He studied medicine at the Medical College of St Bartholomew’s Hospital, University of London, UK, was then at the Royal Marsden Hospital, and completed a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine as well as a visiting fellowship at DFCI in 1993 before joining DFCI as faculty in 1994.

Professor Richardson’s research has been pivotal in the clinical development of numerous novel drugs and monoclonal antibodies for the treatment of multiple myeloma over the last 20 years.

Professor Richardson serves on the editorial boards of several leading journals, holds advisory board and steering committee positions in many organizations, was a founding chairman of the Multiple Myeloma Research Consortium, and was the inaugural chair of the Alliance Myeloma Committee from 2011 to 2021 for the requisite 10-year term. He is the recipient of numerous prestigious awards and has published extensively with over 800 papers, reviews, and chapters in his field.

AGENDA
09:30–09:35	Welcome and Introduction Katja Weisel University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
09:35–10:00	Immunotherapies in Multiple Myeloma – Latest Clinical Developments and Real-World Experience Salomon Manier Lille University Hospital and University of Lille, Lille, France
10:00–10:20	Emerging Preclinical Data for Novel Oral Agents in Multiple Myeloma Charlotte Pawlyn The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
10:20–10:45	Emerging Clinical Data for Novel Oral Agents in Multiple Myeloma Paul G. Richardson Dana-Farber Cancer Institute, Boston, MA, USA
10:45–11:00	Panel Discussion and Summary Close All faculty

Evaluate this session

Download the program

Industry Symposium

Harnessing the Immune System:
New Emerging Data in Multiple Myeloma

Friday 24 May 2024 | 09:30–11:00 CEST
Paris, France

FACULTY

Scientific Program

Exhibition

Registration

Information

Industry Symposium

Harnessing the Immune System: New Emerging Data in Multiple Myeloma

Friday 24 May 2024 | 09:30–11:00 CEST Paris, France

FACULTY

Scientific Program

Exhibition

Registration

Information

Harnessing the Immune System:
New Emerging Data in Multiple Myeloma

Friday 24 May 2024 | 09:30–11:00 CEST
Paris, France